Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SOD1 | P00441 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19240345 | 0.87 | ACHE (0.49) | ACHECYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL20288428 | 0.85 | ACHE (0.47) | ACHECYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL7807816 | 0.82 | ACHE (0.47) | ACHECYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL30605888 | 0.82 | NPSR1 (0.57) | DRD1LMNANPSR1HTTMEN1 | |
| SCHEMBL12247693 | 0.81 | CETP (0.54) | ACHECYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL102298 | 0.78 | KIF11 (0.49) | ACHECYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL12163571 | 0.78 | CYP3A4 (0.45) | ACHECYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL13649193 | 0.78 | CYP3A4 (0.47) | ACHECYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL18118971 | 0.77 | CYP3A4 (0.59) | ACHECYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL28407343 | 0.77 | CYP3A4 (0.50) | ACHECYP3A4CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | US | disclosed |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-20 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | ACHE 2784/4885CYP3A4 819/4885CYP2C9 2239/4885 |
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ACAT2, ACAT1, DGAT1 | ACHE 1518/4885CYP3A4 1599/4885CYP2C9 1529/4885 |
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | ACHE 3737/4885CYP3A4 1083/4885CYP2C9 2087/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ACHE 4370/4885CYP3A4 133/4885CYP2C9 646/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | ACHE 4072/4885CYP3A4 878/4885CYP2C9 1740/4885 |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | ACHE 2271/4885CYP3A4 4362/4885CYP2C9 4598/4885 |
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | ACHE 3237/4885CYP3A4 2349/4885CYP2C9 3204/4885 |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ACHE 4370/4885CYP3A4 133/4885CYP2C9 646/4885 |
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | ACHE 2490/4885CYP3A4 3048/4885CYP2C9 3318/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ACHE 4370/4885CYP3A4 133/4885CYP2C9 646/4885 |
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | ACHE 3737/4885CYP3A4 1083/4885CYP2C9 2087/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | ACHE 3311/4885CYP3A4 2959/4885CYP2C9 3004/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | ACHE 3872/4885CYP3A4 544/4885CYP2C9 285/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | ACHE 3439/4885CYP3A4 2202/4885CYP2C9 2608/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | ACHE 4834/4885CYP3A4 1863/4885CYP2C9 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.